Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

March 31, 2019

Study Completion Date

January 31, 2020

Conditions
Diabetes Mellitus
Interventions
BIOLOGICAL

CLBS03 Low Dose

BIOLOGICAL

CLBS03 High Dose

BIOLOGICAL

Placebo

Trial Locations (15)

32610

University of Florida, Gainesville

33136

University of Miami, Diabetes Research Institute, Miami

37232

Vanderbilt Eskind Diabetes Clinic, Nashville

46202

Indiana University, Indianapolis

55455

University of Minnesota, Minneapolis

57104

Sanford Research, Sioux Falls

58122

Sanford Research, Fargo

64108

Children's Mercy Kansas City, Kansas City

77030

Baylor College of Medicine / Texas Children's Hospital, Houston

80045

Barbara Davis Center for Diabetes, Aurora

92123

Rady Children's Hospital, San Diego

94143

University of California, San Francisco, San Francisco

97239

Oregon Health Science University, Portland

06519

Yale University School of Medicine, New Haven

02215

Joslin Diabetes Center, Boston

Sponsors
All Listed Sponsors
collaborator

Sanford Health

OTHER

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

Lisata Therapeutics, Inc.

INDUSTRY

NCT02691247 - Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study) | Biotech Hunter | Biotech Hunter